CSI President Dr. Robert Melamede Testified Yesterday at Denver Hearing Which Stopped Attempt to Restrict Patients' Access to Medical Marijuana; Cannabis Science Plans for End of Marijuana Prohibition

SAN FRANCISCO, CA -- (MARKET WIRE) -- Cannabis Science Inc. (OTCBB: CBIS), an emerging cannabis pharmaceutical company, is proud to report that its CEO, Dr. Robert Melamede, Ph.D., spoke yesterday at a Denver hearing in opposition to an attempt to undermine a voter-approved constitutional amendment allowing the use of marijuana for medical purposes.

Colorado's state health board voted 6-3 Monday night to reject a move to limit suppliers of medical marijuana to helping only five patients at a time. Dr. Melamede pointed out that such restrictions would make it much more difficult for patients to get affordable medical marijuana.

Dr. Melamede explained, "Although Cannabis Science is committed to developing cannabis-based pharmaceuticals for FDA approval, the company's business strategy is based on the assumption that marijuana prohibition will end, and its products will have to compete with 'over-the-counter' products of the sort already available in medical marijuana dispensaries."

According to the Associated Press, there are 9,112 people registered to use medical marijuana in Colorado, up 2,000 just in the last month. Ron Hyman, the state health department registrar who oversees the medical marijuana registry, predicted that 15,000 people will be signed up by the end of the year. This rapid growth demonstrates the huge need for cannabis-based medicines.

Cannabis Science Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.